Ince A, Yazici Y, Hamuryudan V, Yazici H
Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Turkey.
Clin Rheumatol. 1996 Sep;15(5):491-4. doi: 10.1007/BF02229648.
To assess the frequency and clinical characteristics of methotrexate (MTX) oral toxicity in rheumatoid arthritis (RA) patients, 51 RA patients receiving MTX and 46 RA patients not receiving MTX were studied. A questionnaire, the credibility of which was tested on four separate patient groups including a group with Behcet's Syndrome, was used as a tool to determine the prevalence of stomatitis by a blind observer. In this first controlled study of the oral toxicity of MTX, prevalence of stomatitis was found in 37.2% in the group taking MTX and 19.5% in the group not taking MTX (P = 0.054). No statistical differences were detected with respect to number, duration, frequency, and site of stomatitis. Two of the 51 MTX taking patients temporarily reduced their MTX dosage and only one patient temporarily terminated MTX treatment. MTX and toxicity is usually of no major clinical concern in the treatment of RA.
为评估类风湿关节炎（RA）患者甲氨蝶呤（MTX）口服毒性的发生率及临床特征，对51例接受MTX治疗的RA患者和46例未接受MTX治疗的RA患者进行了研究。采用一份问卷作为工具，由一名盲法观察者来确定口腔炎的患病率，该问卷在包括白塞病患者组在内的四个不同患者群体中进行了信效度检验。在这项关于MTX口服毒性的首次对照研究中，服用MTX组的口腔炎患病率为37.2%，未服用MTX组为19.5%（P = 0.054）。在口腔炎的数量、持续时间、发作频率和部位方面未检测到统计学差异。51例服用MTX的患者中有2例暂时减少了MTX剂量，只有1例患者暂时终止了MTX治疗。在RA治疗中，MTX及其毒性通常不是主要的临床关注点。
